Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Altus Pharmaceuticals has announced the completion of the last patient visit of the Trizytek Phase III efficacy trial. In this trial, Altus is evaluating the efficacy of an oral, non-porcine enzyme replacement therapy for cystic fibrosis patients with exocrine pancreatic insufficiency.
Subscribe to our email newsletter
The Digest efficacy trial tested a one capsule per-meal dosing regimen and will study fat, protein and carbohydrate absorption in cystic fibrosis patients with exocrine pancreatic insufficiency.
In parallel with the efficacy trial, Altus is conducting a long-term safety study to evaluate Trizytek following one year of open-label treatment.
Georges Gemayel, president and CEO of Altus, said: “Completing the last patient visit of the Phase III efficacy trial marks an important milestone in the development of Trizytek. This news confirms that we are on track to report top-line Trizytek efficacy data in the third quarter of 2008.”